ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,127.79
1.26%
Dow Jones
38,675.68
1.18%
US Dollar vs MXN
16.9724
0.00%
Brent Oil
82.765
0.00%
Bitcoin
63,763.59
-0.20%
Registration Strip Icon for monitor Monitoree múltiples cotizaciones en tiempo real de los principales intercambios, como la Bolsa de Valores de Londres, NASDAQ, NYSE, AMEX, Bovespa y más.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. AVEO Pharmaceuticals Inc (AVEO)

  7. AVEO Pharmaceuticals Inc (AVEO) Noticias

AVEO

AVEO Pharmaceuticals (AVEO)

AVEO Pharmaceuticals Inc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:AVEO
FechaHoraFuenteTítuloSímboloCompañía
28/03/202414:22GlobeNewswire Inc.CORRECTION – AVEO Oncology Announces Appointment of Chief Medical Officer and Formation of Scientific Advisory CommitteeNASDAQ:AVEOAVEO Pharmaceuticals Inc
25/03/202407:10GlobeNewswire Inc.AVEO Oncology Announces Appointment of Chief Medical Officer and Formation of Scientific Advisory CommitteeNASDAQ:AVEOAVEO Pharmaceuticals Inc
06/02/202407:10GlobeNewswire Inc.AVEO Oncology Announces Publication of Long-Term Survival in Patients With Relapsed/Refractory Advanced Renal Cell Carcinoma Treated With Tivozanib: Analysis of the Phase III TIVO-3 Trial in The OncologistNASDAQ:AVEOAVEO Pharmaceuticals Inc
16/01/202406:30GlobeNewswire Inc.AVEO Oncology Enrolls First Patient in Pivotal FIERCE-HN Clinical Trial to Evaluate Ficlatuzumab in Combination with ERBITUX® (cetuximab) in Patients with HPV-negative Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)NASDAQ:AVEOAVEO Pharmaceuticals Inc
30/01/202315:08Edgar (US Regulatory)Termination of Registration of a Class of Security Under Section 12(g) (15-12g)NASDAQ:AVEOAVEO Pharmaceuticals Inc
24/01/202305:07Edgar (US Regulatory)Notice of Effectiveness (effect)NASDAQ:AVEOAVEO Pharmaceuticals Inc
19/01/202316:20Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:AVEOAVEO Pharmaceuticals Inc
19/01/202316:05Edgar (US Regulatory)Notification Filed by National Security Exchange to Report the Removal From Listing and Registration of Matured, Redeemed or Retired Securities Initial Filing Amendments (25-nse)NASDAQ:AVEOAVEO Pharmaceuticals Inc
19/01/202315:47Edgar (US Regulatory)Post-effective Amendment to Registration Statement (pos Am)NASDAQ:AVEOAVEO Pharmaceuticals Inc
19/01/202315:44Edgar (US Regulatory)Post-effective Amendment to an S-8 Filing (s-8 Pos)NASDAQ:AVEOAVEO Pharmaceuticals Inc
19/01/202315:35GlobeNewswire Inc.LG Chem Completes Acquisition of AVEO OncologyNASDAQ:AVEOAVEO Pharmaceuticals Inc
18/01/202307:41Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:AVEOAVEO Pharmaceuticals Inc
23/12/202215:02Edgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)NASDAQ:AVEOAVEO Pharmaceuticals Inc
25/11/202207:09Edgar (US Regulatory)Proxy Statement - Merger or Acquisition (definitive) (defm14a)NASDAQ:AVEOAVEO Pharmaceuticals Inc
15/11/202207:33Edgar (US Regulatory)Proxy Statement - Merger or Acquisition (preliminary) (prem14a)NASDAQ:AVEOAVEO Pharmaceuticals Inc
11/11/202216:37ValueWalkIs Mid-Cap Neurocrine Biosciences A Buy After Blowout Q3 Report?NASDAQ:AVEOAVEO Pharmaceuticals Inc
09/11/202222:26TipRanksSVB Securities Sticks to Its Hold Rating for AVEO Pharma (AVEO)NASDAQ:AVEOAVEO Pharmaceuticals Inc
09/11/202222:16TipRanksAVEO Pharma (AVEO) Receives a Hold from Robert W. BairdNASDAQ:AVEOAVEO Pharmaceuticals Inc
07/11/202215:11Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:AVEOAVEO Pharmaceuticals Inc
01/11/202216:02Edgar (US Regulatory)Amended Statement of Beneficial Ownership (sc 13d/a)NASDAQ:AVEOAVEO Pharmaceuticals Inc
28/10/202216:05TipRanksJonesTrading Reaffirms Their Hold Rating on AVEO Pharma (AVEO)NASDAQ:AVEOAVEO Pharmaceuticals Inc
24/10/202207:50TipRanksAnalysts Conflicted on These Healthcare Names: AVEO Pharma (AVEO) and HCA Healthcare (HCA)NASDAQ:AVEOAVEO Pharmaceuticals Inc
18/10/202214:15Dow Jones NewsAVEO Pharma Shares Soar After LG Chem Takeover NewsNASDAQ:AVEOAVEO Pharmaceuticals Inc
18/10/202212:45TipRanksH.C. Wainwright downgrades AVEO Pharma (AVEO) to a HoldNASDAQ:AVEOAVEO Pharmaceuticals Inc
18/10/202206:54TipRanksAVEO Soars on LG Chem DealNASDAQ:AVEOAVEO Pharmaceuticals Inc
18/10/202206:35TipRanksJonesTrading Keeps Their Buy Rating on AVEO Pharma (AVEO)NASDAQ:AVEOAVEO Pharmaceuticals Inc
18/10/202205:26Dow Jones NewsAVEO Pharmaceuticals Shares Soar on Takeover by LG ChemNASDAQ:AVEOAVEO Pharmaceuticals Inc
18/10/202205:05Dow Jones NewsLG Chem to Acquire AVEO Pharmaceuticals for $566 MillionNASDAQ:AVEOAVEO Pharmaceuticals Inc
13/10/202223:05TipRanksAVEO Pharma (AVEO) Gets a Buy from Robert W. BairdNASDAQ:AVEOAVEO Pharmaceuticals Inc
13/10/202222:55TipRanksAVEO Pharma (AVEO) Receives a Buy from SVB SecuritiesNASDAQ:AVEOAVEO Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:AVEO

Su Consulta Reciente

NASDAQ
NVDA
NVIDIA
FX
USDMXN
US Dollar vs MXN
NYSE
MRK
Merck
NASDAQ
AAPL
Apple
NYSE
MCD
McDonalds
NYSE
DIS
Walt Disney
NYSE
BAC
Bank of America
CCOM
US500
US 500
COIN
SOLUSD
Solana
COIN
ETHUSD
Ethereum
NYSE
NKE
Nike
NYSE
XOM
Exxon Mobil
FX
EURMXN
Euro vs MXN
PM
XAUUSD
Gold vs US Dollar
NASDAQ
GOOGL
Alphabet
Delayed Upgrade Clock
ADVFN Logo

México
Empresa
Negocios
Popular
Obtener la aplicación

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados